AR078817A1 - DERIVATIVES OF AMINOPIRIDINE SELECTIVE INHIBITORS OF HUMAN TISSULAR KLK1 CALICREIN, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME IN THE TREATMENT OF RESPIRATORY AND ALLERGIC DISEASES. - Google Patents
DERIVATIVES OF AMINOPIRIDINE SELECTIVE INHIBITORS OF HUMAN TISSULAR KLK1 CALICREIN, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME IN THE TREATMENT OF RESPIRATORY AND ALLERGIC DISEASES.Info
- Publication number
- AR078817A1 AR078817A1 ARP100103978A ARP100103978A AR078817A1 AR 078817 A1 AR078817 A1 AR 078817A1 AR P100103978 A ARP100103978 A AR P100103978A AR P100103978 A ARP100103978 A AR P100103978A AR 078817 A1 AR078817 A1 AR 078817A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- aryl
- cycloalkyl
- alkoxy
- Prior art date
Links
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 title 1
- 102100038297 Kallikrein-1 Human genes 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 17
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 11
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 10
- 125000001424 substituent group Chemical group 0.000 abstract 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 8
- 125000001153 fluoro group Chemical group F* 0.000 abstract 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000002619 bicyclic group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula (1) en donde R1 y R2 se seleccionan independientemente de H, hidroxilo, alquilo C1-10, alcoxi C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-10, heterocicloalquilo, arilo, heteroarilo, ariloalquilo C1-4 y heteroariloalquilo C1-4; R3 se selecciona de H, alquilo C1-10 y alquenilo C2-6; R6 y R7 se seleccionan independientemente de H y alquilo C1-6; R8, R9 y R10 se seleccionan independientemente de H, alquilo C1-10, halo, hidroxilo y alcoxi C1-6; A1 se selecciona de CW y S(O)X; W se selecciona de Y y los grupos de formulas (2) y (3), X se selecciona de alquilo C1-10, alquenilo C2-6, cicloalquilo C3-10, heterocicloalquilo, arilo, heteroarilo y ariloalquilo C1-4; Y se selecciona de -CHRXRY y -C(RW)=CRVRZ; RX se selecciona de H, alquilo C1-10, alquenilo C2-6, cicloalquilo C3-10, arilo, ariloalquilo C1-4, ariloalquenilo C2-4 y heteroariloalquilo C1-4; RY se selecciona de H y alquilo C1-10; o RX y RY junto con el átomo de carbono al que están unidos forman un grupo cicloalquilo C3-10; RV se selecciona de arilo y heteroarilo; RW se selecciona de H, fluoro y alquilo C1-10; o RV y RW junto con los átomos de carbono a los que están unidos forman un grupo seleccionado de arilo y heteroarilo; RZ se selecciona de H, alquilo C1-10 y fluoro; R4 y R5 se seleccionan independientemente de H, alquilo C1-10, alquenilo C2-6, cicloalquilo C3-10, heterocicloalquilo, arilo, heteroarilo, ariloalquilo C1-4 y heteroariloalquilo C1-4; Ra y Rb se seleccionan independientemente de H, alquilo C1-10, alquenilo C2-6, cicloalquilo C3-10, heterocicloalquilo, arilo, heteroarilo, ariloalquilo C1-4, ariloalquenilo C2-4, heteroariloalquilo C1-4, -SO2alquilo C1-6, -SO2arilo y SO2ariloalquilo C1-4; o Ra y Rb junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente insaturado de 4-7 miembros que contiene N, que contiene opcionalmente otro heteroátomo seleccionado de N, O y S, y opcionalmente sustituido con carbono con 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, halo, CN e hidroxilo; dicho anillo que contiene N puede también estar opcionalmente fusionado a un grupo arilo; o Ra y Rb junto con los átomos a los que están unidos pueden formar un anillo aromático mono o bicíclico de 5, 6, 9 o 10 miembros que contiene N, que contiene opcionalmente otro heteroátomo seleccionado de N, O y S, y opcionalmente sustituido con carbono con 1, 2 o 3 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, halo, CN, arilo, COOR15 e hidroxilo; en donde alquilo puede estar opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de cicloalquilo C3-10, alcoxi C1-6, fenoxi, OH, CN, CF3, COOR11, fluoro y NR11R12; alquenilo puede estar opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de cicloalquilo C3-10, alcoxi C1-6, OH, CN, CF3, COOR11, fluoro y NR11R12; alquinilo puede estar opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de cicloalquilo C3-10, alcoxi C1-6, OH, CN, CF3, COOR11, fluoro y NR11R12; alcoxi puede estar opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de cicloalquilo C3-10, OH, CN, CF3, COOR11, fluoro y NR11R12; cicloalquilo es un anillo hidrocarburo mono o bicíclico no aromático, opcionalmente fusionado a un grupo arilo, en donde dicho anillo cicloalquilo contiene opcionalmente, cuando es posible, hasta 2 enlaces dobles; y en donde, a menos que se especifique lo contrario, dicho cicloalquilo puede estar opcionalmente sustituido por 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, OH, CN, CF3, COOR11, fluoro y NR11R12; heterocicloalquilo es un anillo mono o bicíclico, no aromático de 3 a 10 miembros unido a C o unido a N, en donde dicho anillo heterocicloalquilo contiene, cuando es posible, 1, 2 o 3 heteroátomos independientemente seleccionados de N, NR11, S(O)q y O; y dicho anillo heterocicloalquilo contiene opcionalmente, cuando es posible, 1 o 2 enlaces dobles, y está opcionalmente sustituido con carbono con 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, OH, CN, CF3, halo, COOR11, NR11R12 y arilo; arilo es un sistema de anillos aromático simple o fusionado que contiene de 6 o 10 átomos de carbono; en donde, a menos que se especifique lo contrario, cada aparicion de arilo puede estar opcionalmente sustituida con hasta 5 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, OH, halo, CN, COOR11, CF3 y NR11R12; heteroarilo es un anillo aromático mono o bicíclico de 5, 6, 9 o 10 miembros, que contiene, cuando es posible, 1, 2 o 3 miembros del anillo independientemente seleccionados de N, NR11, S y O; en donde, a menos que se especifique lo contrario, dicho hetero arilo puede estar opcionalmente sustituido con 1, 2 o 3 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, OH, halo, CN, COOR11, CF3 y NR11R12; q es 0, 1 o 2; R11 y R12 se seleccionan independientemente de H y alquilo C1-6; con la condicion de que cuando A1 es CW, W es Y, Y es -C(RW)=CRVRZ y RV y RW junto con los átomos de carbono a los que están unidos forman un grupo heteroarilo, RW no puede ser un átomo de nitrogeno; y tautomeros, estereoisomeros, sales y solvatos farmacéuticamente aceptables del mismo.Claim 1: A compound of formula (1) wherein R1 and R2 are independently selected from H, hydroxy, C1-10 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylC 1-4 alkyl and heteroarylC 1-4 alkyl; R3 is selected from H, C1-10 alkyl and C2-6 alkenyl; R6 and R7 are independently selected from H and C1-6 alkyl; R8, R9 and R10 are independently selected from H, C1-10 alkyl, halo, hydroxyl and C1-6 alkoxy; A1 is selected from CW and S (O) X; W is selected from Y and the groups of formulas (2) and (3), X is selected from C 1-10 alkyl, C 2-6 alkenyl, C 3-10 cycloalkyl, heterocycloalkyl, aryl, heteroaryl and C 1-4 arylalkyl; And it is selected from -CHRXRY and -C (RW) = CRVRZ; RX is selected from H, C 1-10 alkyl, C 2-6 alkenyl, C 3-10 cycloalkyl, aryl, C 1-4 arylalkyl, C 2-4 arylalkenyl and C 1-4 heteroaryloalkyl; RY is selected from H and C1-10 alkyl; or RX and RY together with the carbon atom to which they are attached form a C3-10 cycloalkyl group; RV is selected from aryl and heteroaryl; RW is selected from H, fluoro and C1-10 alkyl; or RV and RW together with the carbon atoms to which they are attached form a group selected from aryl and heteroaryl; RZ is selected from H, C1-10 alkyl and fluoro; R4 and R5 are independently selected from H, C1-10 alkyl, C2-6 alkenyl, C3-10 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-4 arylalkyl and C1-4 heteroarylalkyl; Ra and Rb are independently selected from H, C1-10 alkyl, C2-6 alkenyl, C3-10 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-4 arylalkyl, C2-4 arylalkenyl, C1-4 heteroarylalkyl, C1-6 alkyl , -SO2aryl and SO2arylC 1-4 alkyl; or Ra and Rb together with the atoms to which they are attached can form a 4-7 membered saturated or partially unsaturated ring containing N, optionally containing another heteroatom selected from N, O and S, and optionally substituted with carbon with 1 or 2 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, halo, CN and hydroxyl; said ring containing N may also be optionally fused to an aryl group; or Ra and Rb together with the atoms to which they are attached can form a mono, bicyclic, 5, 6, 9 or 10-membered aromatic ring containing N, optionally containing another heteroatom selected from N, O and S, and optionally substituted with carbon with 1, 2 or 3 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, halo, CN, aryl, COOR15 and hydroxyl; wherein alkyl may be optionally substituted with 1 or 2 substituents independently selected from C3-10 cycloalkyl, C1-6 alkoxy, phenoxy, OH, CN, CF3, COOR11, fluoro and NR11R12; alkenyl may be optionally substituted with 1 or 2 substituents independently selected from C3-10 cycloalkyl, C1-6 alkoxy, OH, CN, CF3, COOR11, fluoro and NR11R12; alkynyl may be optionally substituted with 1 or 2 substituents independently selected from C3-10 cycloalkyl, C1-6 alkoxy, OH, CN, CF3, COOR11, fluoro and NR11R12; Alkoxy may be optionally substituted with 1 or 2 substituents independently selected from C3-10 cycloalkyl, OH, CN, CF3, COOR11, fluoro and NR11R12; cycloalkyl is a non-aromatic mono or bicyclic hydrocarbon ring, optionally fused to an aryl group, wherein said cycloalkyl ring optionally contains, when possible, up to 2 double bonds; and wherein, unless otherwise specified, said cycloalkyl may be optionally substituted by 1 or 2 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, OH, CN, CF3, COOR11, fluoro and NR11R12; heterocycloalkyl is a mono or bicyclic, non-aromatic 3 to 10 membered ring attached to C or attached to N, wherein said heterocycloalkyl ring contains, when possible, 1, 2 or 3 heteroatoms independently selected from N, NR11, S (O ) q and O; and said heterocycloalkyl ring optionally contains, when possible, 1 or 2 double bonds, and is optionally substituted with carbon with 1 or 2 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, OH, CN, CF3, halo, COOR11 , NR11R12 and aryl; aryl is a simple or fused aromatic ring system containing 6 or 10 carbon atoms; wherein, unless otherwise specified, each occurrence of aryl may be optionally substituted with up to 5 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, OH, halo, CN, COOR11, CF3 and NR11R12; heteroaryl is a mono, bicyclic aromatic ring of 5, 6, 9 or 10 members, containing, when possible, 1, 2 or 3 ring members independently selected from N, NR11, S and O; wherein, unless otherwise specified, said hetero aryl may be optionally substituted with 1, 2 or 3 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, OH, halo, CN, COOR11, CF3 and NR11R12; q is 0, 1 or 2; R11 and R12 are independently selected from H and C1-6 alkyl; with the proviso that when A1 is CW, W is Y, Y is -C (RW) = CRVRZ and RV and RW together with the carbon atoms to which they are attached form a heteroaryl group, RW cannot be an atom of nitrogen; and pharmaceutically acceptable tautomers, stereoisomers, salts and solvates thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25560609P | 2009-10-28 | 2009-10-28 | |
| GBGB0918922.6A GB0918922D0 (en) | 2009-10-28 | 2009-10-28 | Aminopyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078817A1 true AR078817A1 (en) | 2011-12-07 |
Family
ID=41434814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103978A AR078817A1 (en) | 2009-10-28 | 2010-10-28 | DERIVATIVES OF AMINOPIRIDINE SELECTIVE INHIBITORS OF HUMAN TISSULAR KLK1 CALICREIN, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME IN THE TREATMENT OF RESPIRATORY AND ALLERGIC DISEASES. |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR078817A1 (en) |
| GB (1) | GB0918922D0 (en) |
| TW (1) | TW201119654A (en) |
| UY (1) | UY32975A (en) |
| WO (1) | WO2011051671A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| US9409880B2 (en) | 2011-01-20 | 2016-08-09 | The Regents Of The University Of Colorado, A Body Corporate | Modulators of TLR3/dsRNA complex and uses thereof |
| GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
| JP2016152772A (en) * | 2013-06-27 | 2016-08-25 | 味の素株式会社 | Novel umami-taste imparting agent |
| CN111138357B (en) * | 2018-11-06 | 2022-11-04 | 天津药物研究院有限公司 | 2-oxo-1, 2-dihydroquinoline derivative, preparation method and medical application thereof |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0147716A3 (en) | 1983-12-24 | 1987-10-28 | ANT Nachrichtentechnik GmbH | Method and apparatus for the encipherable transmission of a series of binary information signals with authenticity check |
| JPS6235216A (en) | 1985-08-09 | 1987-02-16 | Noritoshi Nakabachi | Method and device for measuring thickness of heterogeneous material layer nondestructively |
| US4873253A (en) * | 1987-03-30 | 1989-10-10 | Shosuke Okamoto | Phenylalanine derivative and proteinase inhibitor |
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| GR1001529B (en) | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Process for the obtainment of a new pregna-1,4-diene-3,20-dione -16-17-acetal-21 esters |
| WO1993018007A1 (en) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Novel carbostyril derivative |
| SE9301911D0 (en) | 1993-06-03 | 1993-06-03 | Ab Astra | NEW PEPTIDE DERIVATIVES |
| US5464820A (en) | 1993-06-22 | 1995-11-07 | The University Hospital | Specific inhibitors of tissue kallikrein |
| GB9318637D0 (en) | 1993-09-08 | 1993-10-27 | Ferring Res Ltd | Enzyme inhibitors |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| HRP20020845A2 (en) | 2000-04-27 | 2003-10-31 | Boehringer Ingelheim Pharma | Novel, slow-acting betamimetics, a method for their production and their use as medicaments |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| WO2002070490A1 (en) | 2001-03-08 | 2002-09-12 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| EP1370521B1 (en) | 2001-03-22 | 2007-12-19 | Glaxo Group Limited | Formanilide derivatives as beta2-adrenoreceptor agonists |
| HU228508B1 (en) | 2001-09-14 | 2013-03-28 | Glaxo Group Ltd | Phenethanolamine derivatives and pharmaceutical composition containing them |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| ES2271365T3 (en) | 2001-12-20 | 2007-04-16 | Bayer Healthcare Ag | DERIVATIVES OF 1,4-DIHIDRO-1,4-DIFENYLPIRIDINE. |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| US7271197B2 (en) | 2002-04-25 | 2007-09-18 | Glaxo Group Limited | Phenethanolamine derivatives |
| EP1507754A1 (en) | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Alkoxy aryl beta-2 adrenergic receptor agonists |
| WO2003101941A2 (en) | 2002-05-31 | 2003-12-11 | Genzyme Corporation | Alpha acyloxyacetamides for kallikrein and urokinase inhibition |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| PE20050130A1 (en) | 2002-08-09 | 2005-03-29 | Novartis Ag | ORGANIC COMPOUNDS |
| WO2004020410A2 (en) | 2002-08-27 | 2004-03-11 | Bayer Healthcare Ag | Dihydropyridinone derivatives as hne inhibitors |
| GB0219896D0 (en) | 2002-08-27 | 2002-10-02 | Bayer Ag | Dihydropyridine derivatives |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| PL375647A1 (en) | 2002-09-10 | 2005-12-12 | Bayer Healthcare Ag | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes |
| EP1539710B1 (en) | 2002-09-10 | 2010-10-27 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclic derivatives |
| DE10246374A1 (en) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 4-(2-alkylamino-1-hydroxyethyl)-3-alkoxy-benzene-1,2-diol derivatives, are beta-mimetics having a long duration of action, useful e.g. for treating asthma, chronic obstructive pulmonary disease or arrhythmia |
| AU2003269316A1 (en) | 2002-10-11 | 2004-05-04 | Pfizer Inc. | Indole derivatives as beta-2 agonists |
| EP1440966A1 (en) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Indole derivatives useful for the treatment of diseases |
| DE60315492T2 (en) | 2002-10-22 | 2008-04-24 | Glaxo Group Ltd., Greenford | MEDICALLY USEFUL ARYLETHANOLAMINE COMPOUNDS |
| SI1556342T1 (en) | 2002-10-28 | 2008-08-31 | Glaxo Group Ltd | Phenethanolamine derivative for the treatment of respiratory diseases |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| JP2004161702A (en) | 2002-11-14 | 2004-06-10 | Hokko Chem Ind Co Ltd | Method for producing γ-jasmolactone |
| DE10253220A1 (en) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 2-(N-phenylalkyl-amino)-1-phenyl-ethanol derivatives, are beta-adrenergic agents especially useful for treating inflammatory and obstructive respiratory diseases such as asthma or COPD |
| DE10253282A1 (en) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Treatment of chronic obstructive pulmonary disease, using new or known N-substituted 2-amino-1-(benz-(1,4)-oxazin-3-on-8-yl)-ethanol derivative beta-mimetic agents, suitable for once-daily administration |
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| DE10258695A1 (en) | 2002-12-16 | 2004-06-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 2-(2-hydroxy-2-(3-methylsulfonylamino-4-hydroxyphenyl)ethylamino-4-(pyrid-2-ylamino)-2-methylbutane used e.g. for treating asthma and chronic obstructive pulmonary disease |
| GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
| EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| JP4767842B2 (en) | 2003-04-01 | 2011-09-07 | セラヴァンス， インコーポレーテッド | Diarylmethyl compounds and related compounds having β2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity |
| US7745462B2 (en) | 2003-04-04 | 2010-06-29 | Novartis Ag | Quinoline-2-one derivatives for the treatment of airways diseases |
| US7268147B2 (en) | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
| ATE435862T1 (en) | 2003-05-28 | 2009-07-15 | Theravance Inc | AZABICYCLOALKAN COMPOUNDS AS MUSCARINE RECEPTOR ANTAGONISTS |
| BRPI0410660A (en) | 2003-06-04 | 2006-06-20 | Pfizer | 2-amino-pyridine derivatives as ß2 adrenoreceptor agonists |
| GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| SE0302323D0 (en) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| SE0302324D0 (en) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (en) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| SE0302487D0 (en) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| WO2005033121A2 (en) | 2003-10-03 | 2005-04-14 | King Pharmaceuticals Research & Development, Inc. | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs |
| GB0323701D0 (en) | 2003-10-09 | 2003-11-12 | Glaxo Group Ltd | Formulations |
| GB0324654D0 (en) | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| CA2544422C (en) | 2003-11-03 | 2010-01-19 | Norton Healthcare, Ltd. | Soft steroid compositions for use in dry powder inhalers |
| GB0328490D0 (en) | 2003-12-09 | 2004-01-14 | Glaxo Group Ltd | Medicinal compounds |
| GB0329182D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds |
| US7588681B2 (en) | 2003-12-19 | 2009-09-15 | Shell Oil Company | Systems, methods, and catalysts for producing a crude product |
| DE102004001413A1 (en) | 2004-01-09 | 2005-08-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of chronic obstructive pulmonary disease |
| TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| AU2005214153B2 (en) | 2004-01-22 | 2008-09-18 | Pfizer Inc. | Sulfonamide derivatives for the treatment of diseases |
| AP2378A (en) | 2004-01-22 | 2012-03-08 | Pfizer | Sulfonamide derivatives for the treatment of diseases. |
| DE102004003428A1 (en) | 2004-01-23 | 2005-08-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New long-acting beta-2 agonists, and their use as pharmaceuticals |
| ES2349470T3 (en) | 2004-02-14 | 2011-01-03 | Boehringer Ingelheim International Gmbh | NEW BETA-2-AGONISTS OF LONG-TERM ACTION AND ITS USE AS MEDICATIONS. |
| CA2556463C (en) | 2004-02-19 | 2012-08-14 | Bayer Healthcare Ag | Dihydropyridinone derivatives |
| WO2005082864A1 (en) | 2004-02-26 | 2005-09-09 | Bayer Healthcare Ag | 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors |
| ES2428503T3 (en) | 2004-02-26 | 2013-11-08 | Bayer Intellectual Property Gmbh | 1,4-Diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors |
| WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
| EP1577306A1 (en) | 2004-03-17 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | novel benzoxazinone derivatives as slow-acting betamimetics and use thereof in treatment of respiratory tract diseases |
| EP1577292A1 (en) | 2004-03-17 | 2005-09-21 | Pfizer Limited | Phenylaminoethanol derivatives as beta2 receptor agonists |
| HN2004000023A (en) | 2004-03-22 | 2007-11-23 | Mars Inc | ANIMAL MASCADURE |
| EA200601462A1 (en) | 2004-03-23 | 2007-04-27 | Пфайзер Инк. | CONNECTIONS FOR THE TREATMENT OF DISEASES |
| EP1730103B1 (en) | 2004-03-23 | 2010-05-26 | Pfizer Limited | Formamide derivatives useful as adrenoceptor |
| WO2005092841A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds having beta-agonist activity |
| WO2005092860A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds for the treatment of diseases |
| WO2005095327A1 (en) | 2004-03-31 | 2005-10-13 | Ajinomoto Co., Inc. | Aniline derivatives |
| EP1595873A1 (en) | 2004-05-13 | 2005-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituted cycloalkyl derivatives for the treatment of respiratory diseases |
| EP1789394A1 (en) | 2004-05-13 | 2007-05-30 | Boehringer Ingelheim International Gmbh | Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases |
| DE102004024451A1 (en) | 2004-05-14 | 2005-12-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder formulations for inhalation containing enantiomerically pure beta agonists |
| DE102004024454A1 (en) | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel enantiomerically pure beta agonists, process for their preparation and their use as pharmaceuticals |
| AU2005252226A1 (en) | 2004-06-03 | 2005-12-22 | Theravance, Inc. | Diamine beta2 adrenergic receptor agonists |
| US7317023B2 (en) | 2004-07-21 | 2008-01-08 | Theravance, Inc. | Diaryl ether β2 adrenergic receptor agonists |
| EP1807451A2 (en) | 2004-08-03 | 2007-07-18 | Dyax Corporation | Hk1-binding proteins |
| WO2006016245A1 (en) | 2004-08-05 | 2006-02-16 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| JP2008512470A (en) | 2004-09-10 | 2008-04-24 | セラヴァンス， インコーポレーテッド | Amidine-substituted arylaniline compounds |
| DE102004045648A1 (en) | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New betamimetics for the treatment of respiratory diseases |
| WO2006051373A1 (en) | 2004-11-12 | 2006-05-18 | Pfizer Limited | Compounds for the treatment of diseases |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| EP2051707B1 (en) | 2006-07-31 | 2013-07-17 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| GB0807828D0 (en) * | 2008-04-29 | 2008-06-04 | Vantia Ltd | Aminopyridine derivatives |
-
2009
- 2009-10-28 GB GBGB0918922.6A patent/GB0918922D0/en not_active Ceased
-
2010
- 2010-10-27 UY UY0001032975A patent/UY32975A/en unknown
- 2010-10-27 TW TW099136776A patent/TW201119654A/en unknown
- 2010-10-27 WO PCT/GB2010/001996 patent/WO2011051671A1/en not_active Ceased
- 2010-10-28 AR ARP100103978A patent/AR078817A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB0918922D0 (en) | 2009-12-16 |
| UY32975A (en) | 2011-05-31 |
| TW201119654A (en) | 2011-06-16 |
| WO2011051671A1 (en) | 2011-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067413A1 (en) | HETEROCICLICAL COMPOUNDS CONTAINING CYCLOPENTA [D] PYRIMIDINE INHIBITORS OF AKT PROTEINQUINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHOD OF PREPARATION AND USE OF THE SAME FOR THE TREATMENT OF HYPER-TROLIFERATIVE TIPERIFERATIVE AS-ISSUES | |
| AR085960A1 (en) | 1,3-OXAZINES AS INHIBITORS OF THE BACE1 AND / OR THE BACE2 | |
| AR080865A1 (en) | DERIVATIVES OF SPIROTETRAHYDRONAFTALENE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESS OF PREPARATION AND USE OF THEM TO TREAT NEURODEGENERATIVE DISEASES, AS ALZHEIMER. | |
| AR078817A1 (en) | DERIVATIVES OF AMINOPIRIDINE SELECTIVE INHIBITORS OF HUMAN TISSULAR KLK1 CALICREIN, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME IN THE TREATMENT OF RESPIRATORY AND ALLERGIC DISEASES. | |
| AR086357A1 (en) | INDAZOL DERIVATIVES ACTIVE SUBSTITUTES AS QUINASE INHIBITORS | |
| AR086319A1 (en) | FUSIONED HETEROCICLICAL COMPOUNDS AS IONIC CHANNEL MODULATORS | |
| AR078157A1 (en) | DERIVATIVES OF PIRAZOL- [4,5-D] PIRROLO [2,3-B] PYRIDINE INHIBITORS OF JAK 2 THYROSINQUINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USE OF THE SAME IN THE TREATMENT OF CANCER | |
| CO6251251A2 (en) | DERIVATIVES OF PIRAZINONA AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | |
| AR064608A1 (en) | SUBSTITUTED PIRAZOLO-QUINAZOLINA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. PROCESS FOR THE PREPARATION AND USE OF THE SAME AS ANTICANCER AGENTS. | |
| AR079205A1 (en) | MORPHOLINOTIAZOLS AS POSITIVE ALOSTERIC MODULATORS ALFA 7 | |
| AR054560A1 (en) | SPIROPIPERIDINE AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| AR087760A1 (en) | HETEROCICLILAMINAS AS PI3K INHIBITORS | |
| AR084152A1 (en) | TRIAZOLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF PDE10A, A PROCESS FOR THEIR OBTAINING, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF CNS DISEASES | |
| AR047098A1 (en) | ARILANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEIVER AGONISTS | |
| AR063912A1 (en) | DERIVATIVES OF 1,2,4 OXADIAZOL. PHARMACEUTICAL COMPOSITIONS. | |
| AR085316A1 (en) | PIRROLO DERIVATIVES [2,3-B] PIRIDINE, USEFUL FOR THE MODULATION OF KINASES | |
| AR076435A1 (en) | COMPOUNDS OF REPLACED INDAZOLS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PROCESSES TO OBTAIN THEMSELVES | |
| AR080688A1 (en) | DERIVATIVES OF 2,3-DIHIDRO-1H-INDEN-1-IL-2,7-DIAZASPIRO [3.5] NONANO AS AGONISTS OR INVESTED ANTAGONISTS OF GRELINA | |
| AR076008A1 (en) | DERIVATIVES OF HYDROXIMETHYL-ISOXAZOL GABA A RECEPTOR MODULATORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, METHOD FOR PREPARING THEM AND USE OF THE SAME FOR THE TREATMENT OF ALZHEIMER AND OTHER COGNITIVE DISORDERS. | |
| AR056886A1 (en) | PIRROLOPIRIDINE COMPOUNDS REPLACED INHIBITORS OF KINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN THE TREATMENT OF CANCER | |
| AR079250A1 (en) | DERIVATIVES OF PIRAZOLO [1,5-A] USED PIRIDINE IN THE TREATMENT OF CNS AND CANCER DISEASES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND SYNTHESIS INTERMEDIARY. | |
| PE20141553A1 (en) | TRIAZOLOPYRIDINE COMPOUNDS AS PED10A INHIBITORS | |
| AR082111A1 (en) | FUROPIRIDINES OR CONDENSED TENOPIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM USEFUL TO TREAT PSYCHOTIC AND CENTRAL NERVOUS SYSTEM DISORDERS, AND THE SAME PREPARATION METHOD | |
| AR073043A1 (en) | COMPOUNDS OF POLYSUSTITUTED AZETIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, METHOD OF PREPARATION AND USE OF THE SAME IN THE TREATMENT OF RESPIRATORY, METABOLIC DISEASES AND OF THE CENTRAL NERVOUS SYSTEM, AMONG OTHERS. | |
| AR078164A1 (en) | ISOXAZOLIDINE DERIVATIVES, PROCESS TO PREPARE SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |